Stability of Allopurinol, Amitriptyline Hydrochloride, Carbamazepine, Domperidone, Isoniazid, Ketoconazole, Lisinopril, Naproxen, Paracetamol (Acetaminophen), and Sertraline Hydrochloride in SyrSpend SF PH4 Oral Suspensions. 2016

Hudson C Polonini, and Sharlene Loures, and Edson Peter de Araujo, and Marcos Antônio F Brandão, and Anderson O Ferreira
Ortofarma - Quality Control Laboratories, Minas Gerais State, Brazil.

Oral liquids are safe alternatives to solid dosage forms, notably for elderly and pediatric patients that present dysphagia. The use of ready-to-use suspending vehicles such as SyrSpend SF PH4 is a suitable resource for pharmacists as they constitute a safe and timesaving option that has been studied often. The objective of this study was to evaluate the stability of 10 commonly used active pharmaceutical ingredients (allopurinol 20 mg/mL; amitriptyline hydrochloride 10 mg/mL; carbamazepine 25 mg/mL; domperidone 5 mg/mL; isoniazid 10 mg/mL; ketoconazole 20 mg/mL; lisinopril 1 mg/mL; naproxen 25 mg/mL; paracetamol [acetaminophen] 50 mg/mL; and sertraline hydrochloride 10 mg/mL) compounded in oral suspensions using SyrSpend SF PH4 as the vehicle throughout the study period and stored both at controlled refrigerated (2°C to 8°C) and room temperature (20°C to 25°C). Stability was assessed by means of measuring the percent recovery at varying time points throughout a 90-day period. The quantification of the active pharmaceutical ingredients was performed by high-performance liquid chromatography through a stability-indicating method. Methods were adequately validated. Forced-degradation studies showed that at least one parameter influenced the stability of the active pharmaceutical ingredients. All suspensions were assayed and showed active pharmaceutical ingredient contents between 90% and 110% during the 90-day study period. Although the forced-degradation experiments led to visible fluctuations in the chromatographic responses, the final preparations were stable in the storage conditions. The beyond-use dates of the preparations were found to be at least 90 days for all suspensions, both for controlled refrigerated temperature and room temperature. This confirms that SyrSpend SF PH4 is a stable suspending vehicle for compounding with a broad range of different active pharmaceutical ingredients for different medical usages.

UI MeSH Term Description Entries
D012015 Reference Standards A basis of value established for the measure of quantity, weight, extent or quality, e.g. weight standards, standard solutions, methods, techniques, and procedures used in diagnosis and therapy. Standard Preparations,Standards, Reference,Preparations, Standard,Standardization,Standards,Preparation, Standard,Reference Standard,Standard Preparation,Standard, Reference
D012034 Refrigeration The mechanical process of cooling. Cold Chain,Chain, Cold,Chains, Cold,Cold Chains
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D004355 Drug Stability The chemical and physical integrity of a pharmaceutical product. Drug Shelf Life,Drugs Shelf Lives,Shelf Life, Drugs,Drug Stabilities,Drugs Shelf Life,Drugs Shelf Live,Life, Drugs Shelf,Shelf Life, Drug,Shelf Live, Drugs,Shelf Lives, Drugs
D013535 Suspensions Colloids with liquid continuous phase and solid dispersed phase; the term is used loosely also for solid-in-gas (AEROSOLS) and other colloidal systems; water-insoluble drugs may be given as suspensions. Suspension
D014677 Pharmaceutical Vehicles A carrier or inert medium used as a solvent (or diluent) in which the medicinally active agent is formulated and or administered. (Dictionary of Pharmacy, 1986) Pharmaceutical Vehicle,Vehicle, Pharmaceutical,Vehicles, Pharmaceutical

Related Publications

Hudson C Polonini, and Sharlene Loures, and Edson Peter de Araujo, and Marcos Antônio F Brandão, and Anderson O Ferreira
January 2020, International journal of pharmaceutical compounding,
Hudson C Polonini, and Sharlene Loures, and Edson Peter de Araujo, and Marcos Antônio F Brandão, and Anderson O Ferreira
January 2017, International journal of pharmaceutical compounding,
Hudson C Polonini, and Sharlene Loures, and Edson Peter de Araujo, and Marcos Antônio F Brandão, and Anderson O Ferreira
January 2020, International journal of pharmaceutical compounding,
Hudson C Polonini, and Sharlene Loures, and Edson Peter de Araujo, and Marcos Antônio F Brandão, and Anderson O Ferreira
November 2016, European journal of hospital pharmacy : science and practice,
Hudson C Polonini, and Sharlene Loures, and Edson Peter de Araujo, and Marcos Antônio F Brandão, and Anderson O Ferreira
January 2020, International journal of pharmaceutical compounding,
Hudson C Polonini, and Sharlene Loures, and Edson Peter de Araujo, and Marcos Antônio F Brandão, and Anderson O Ferreira
January 2016, Journal of pharmaceutical and biomedical analysis,
Hudson C Polonini, and Sharlene Loures, and Edson Peter de Araujo, and Marcos Antônio F Brandão, and Anderson O Ferreira
January 2012, International journal of pharmaceutical compounding,
Hudson C Polonini, and Sharlene Loures, and Edson Peter de Araujo, and Marcos Antônio F Brandão, and Anderson O Ferreira
January 2013, International journal of pharmaceutical compounding,
Copied contents to your clipboard!